Navigation Links
ACT PLUS Automated Coagulation Timer System

ProductsACT PLUS Automated Coagulation Timer System
Company Medtronic Inc.
Item ACT PLUS Automated Coagulation Timer System
Features BUILT-IN EFFICIENCY
  • Immediate results mean anticoagulant dosages can be adjusted quickly.
  • Dual-well testing provides the extra confidence that only duplicate results provide.
  • Because less than 1 ml of blood is required for each test, the ACT Plus System is especially suited for patients with small blood volumes.
  • Bar Code Scanner (optional) is used for accurate entry of cartridge and control lot numbers and expiration dates.
  • SCIENTIFIC ACCURACY

  • Full range of lyophilized controls and an electronic control are available to verify instrument, cartridge and operator performance and meet regulatory guidelines for testing.
  • Lyophilized controls are easy to reconstitute and provide enough volume to test multiple instruments.
  • Electronic control provides multiple-level testing in one device.
  • NEW, MODULAR DESIGN

  • Quiet operation
  • Easy to clean
  • User-friendly switches
  • Convenient, comfortable carrying handle
  • Description Medtronic, the worlds leading medical technology company and a key participant in blood management for more than a decade, introduces a new generation Automated Coagulation Timer. The ACT Plus System is a microprocessor-controlled electromechanical coagulation instrument designed to determine coagulation endpoints in whole blood, citrated whole blood, and plasma samples. Clotting-time results are presented on the instruments Clot Time Display (CTD) and Liquid Crystal Display (LCD) screens.

    The ACT Plus System provides long-term data storage and retrieval, with access to previous patient and quality control test data. Test results are stored in the order in which they are performed. The ability to externally transfer or save data to a floppy disk enhances the systems versatility.

    Manufactured by the Medtronic Biologic Therapeutics and Diagnostics business, the ACT Plus System combines a trusted standard in precise clot detection technology with state-of-the-art user enhancements including data management and connectivity-ready capabilities

    Info Medtronic Inc.
    Customer Service: (800) 551-5544
    Web site: http://www.medtronic.com/

    Related medicine products :

    1. Dade DAC II Automated Cell Washer
    2. Sysmex XE-2100™ Automated Hematology Analyzer
    3. Automated Blood Coagulation Analyzer
    4. Microplate ELISA Washers - Automated Microplate Washer
    5. ACS:180 SE Automated Chemiluminescence System
    6. Semi-Automated Chemistry Analyzer
    7. NP-3S Automated Chart Projector
    8. CP-690E Automated Projector
    9. Clinitek Atlas Automated Urine Chemistry Analyzer (Rack)
    10. Clinitek Atlas Automated Urine Chemistry Analyzer (Carousel)
    11. ARIS Automated Retinal Imaging System
    Solid 16 mm blades. Self-locking mechanism. Dull finish....
    Fenestrated 16 mm blades. Self-locking mechanism. Dull finish....
    ... Kawesch-Lancaster Lasik speculum has wide ... to provide clearance for the ... retract the lids and lashes ... the microkeratome. The blades are ...
    Adjustable wire speculum with 17 mm open blades. Lid tension adjustable throughout procedure with thumb screw control. Angled 45 degrees....
    Medicine Products:
    (Date:7/30/2014)... is being financially exploited often by their own ... poor and black people. It merits the scrutiny of ... about the dignity and well-being of older Americans, says ... the US. She led one of the largest American ... appear in the Journal of General Internal Medicine ...
    (Date:7/30/2014)... A survey of beds within a large teaching hospital in ... with dimensional standards put in place to minimise the risk ... Age and Ageing , therefore emphasises the need for careful ... as well as the need for monitoring and maintenance of ... devices to prevent people falling from bed. However, although the ...
    (Date:7/30/2014)... The report entitled “Global Pulse Oximetry Market: ... market dynamics and changing trends in the global pulse ... market sizing of the global pulse oximetry market and ... the same. It further captures the global market share ... market. Further, the report discusses the domestic market of ...
    (Date:7/30/2014)... 2014 Los Angeles cosmetic dentist ... treatments that can help patients create their dream smiles ... and gums form the foundation of smile confidence, but ... chips, misshapen teeth or stains may not interfere with ... appearance. The right cosmetic treatments can eliminate chips, erase ...
    (Date:7/30/2014)... Building ENT and Allergy Associates (ENTA) ... practice in Westchester County takes the best of everything. ... underlying corporate structure and protocols, and a staff that ... leading Chief Financial Officer to help run it. According ... what it possesses. In fact, in the WCBJ’s July ...
    Breaking Medicine News(10 mins):Health News:Older adults are at risk of financial abuse 2Health News:High frequency of potential entrapment gaps in hospital beds 2Health News:Global Pulse Oximetry Market 2018 Opportunities and Trends Now Available at MarketReportsOnline.com 2Health News:Global Pulse Oximetry Market 2018 Opportunities and Trends Now Available at MarketReportsOnline.com 3Health News:Los Angeles Cosmetic Dentist, Dr. Poneh Ghasri, Now Offers Comprehensive Cosmetic Dental Treatments 2Health News:Los Angeles Cosmetic Dentist, Dr. Poneh Ghasri, Now Offers Comprehensive Cosmetic Dental Treatments 3Health News:The Leading Ear, Nose, and Throat Practice in Westchester County Has One of the Leading CFO’s in Westchester County! 2Health News:The Leading Ear, Nose, and Throat Practice in Westchester County Has One of the Leading CFO’s in Westchester County! 3
    ... upright walking of humans? The discovery of four ... (quadrupedality) may help us understand how humans, unlike other primates, ... legs, a scientist will tell the annual conference of the ... The quadrupedal families in Turkey previously attracted attention in 2005, ...
    ... those with normal version of particular gene respond well ... -- Colon cancer patients who have the normal version ... from a combination treatment that includes adding the targeted ... cancer patients have the normal, or "wild-type" form of ...
    ... Widely prescribed blood-boosters might stimulate malignant cells, hasten death, ... Drugs used widely to treat anemia in cancer patients ... individuals, but researchers report they may found a way ... may have a test to predict whether a patient ...
    ... prevent malignancies, study suggests , , SUNDAY, June 1 (HealthDay ... day have value in helping to prevent lung cancer. ... cox-2 inhibitor on the U.S. market, may reduce levels ... The team presented its findings Sunday at the American ...
    ... CHICAGO, June 1 The combination of two different ... according to a University of Pittsburgh Cancer Institute (UPCI) ... American Society of Clinical Oncology (ASCO) in Chicago. , ... UPCI combined two biotherapies treatments that stimulate the ...
    ... study says , , SUNDAY, June 1 (HealthDay News) -- People ... are much more likely than other people to develop certain ... a cancer of the lymph nodes, has a cure rate ... future risk of developing second cancers other than HD, according ...
    Cached Medicine News:Health News:Genetic mutation linked to walking on all 4s 2Health News:Genetic mutation linked to walking on all 4s 3Health News:Erbitux Works Well for Two-Thirds of Colon Cancer Patients 2Health News:Erbitux Works Well for Two-Thirds of Colon Cancer Patients 3Health News:Anemia Drugs May Speed Tumor Growth in Some Cancer Patients 2Health News:Anemia Drugs May Speed Tumor Growth in Some Cancer Patients 3Health News:Celebrex May Reduce Levels of Lung Cancer Biomarker 2Health News:Celebrex May Reduce Levels of Lung Cancer Biomarker 3Health News:Young Hodgkin Survivors Face Later Risk of Second Cancers 2
    (Date:7/30/2014)... , July 30, 2014  Regeneron Pharmaceuticals, Inc. ... and NYSE: SNY ) today announced that ... people with hypercholesterolemia met their primary efficacy endpoint of ... cholesterol (LDL-C) at 24 weeks compared to placebo or ... PCSK9 (proprotein convertase subtilisin/kexin type 9). In ...
    (Date:7/30/2014)... SAN DIEGO , July 30, 2014  Eisai ... announced today that an article based on post-hoc analyses from ... Weight Loss While on Lorcaserin, Diet, and Exercise as a ... the online issue of Obesity , the official peer ... analyses was to identify whether there is an early treatment ...
    (Date:7/30/2014)... 2014  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), ... its expertise in opioid antagonists, announced today that ... prominent international research and development foundation. ... research-based initiatives, including those addressing health issues. Lightlake ... delivery of naloxone that could widely expand its ...
    Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3